US FDA approves Boostrix maternal immunisation

RNS Number : 2601C

GSK PLC

10 October 2022

 

Issued: 10 October 2022, London

For media and investors only

US FDA approves Boostrix for immunisation during pregnancy for the prevention of whooping cough in newborn infants

Boostrix is the first vaccine in the US to help protect infants younger than two months from pertussis (whooping cough)

 

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Boostrix (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed [Tdap]) for immunisation during the third trimester of pregnancy to help prevent pertussis (whooping cough) in infants less than two months of age.

Since 2010, the Centers for Disease Control and Prevention (CDC) has reported 15,000 to 48,000 pertussis cases among people of all ages in the United States each year.¹ Infants are at high risk of complications from whooping cough because their immune systems are still developing.¹

According to the CDC, the Tdap vaccination given during pregnancy provides the best protection to infants against whooping cough. Vaccination passes protective antibodies to babies before birth to protect them in their first months of life² .

Roger Connor, President, Vaccines and Global Health, GSK, said: "We're immensely proud to have the first-ever Tdap vaccine approved by the FDA specifically for use during pregnancy. We believe this approval may help protect more infants from the potentially life-threatening implications of whooping cough."

Boostrix is currently approved in over 80 countries worldwide, including the US, most European Union countries, Canada, Australia and New Zealand for immunisation against tetanus, diphtheria and pertussis.

About BOOSTRIX

Boostrix is indicated in the US for:

· Active booster immunisation against tetanus, diphtheria and pertussis in individuals aged 10 years and older .

· Immunisation during the third trimester of pregnancy to help prevent pertussis (whooping cough) in infants less than two months of age.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at www.gsk.com/company .

GSK enquiries
Media:	Tim Foley	[phone]	(London)
	Dan Smith	[phone]	(London)
	Kathleen Quinn	[phone]	(Washington DC)
	Lyndsay Meyer	[phone]	(Washington DC)
Investor Relations:	Nick Stone	[phone]	(London)
	James Dodwell	[phone]	(London)
	Mick Readey	[phone]	(London)
	Josh Williams	[phone]	(London)
	Jeff McLaughlin	[phone]	(Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK's Q2 Results for 2022 and any impacts of the COVID-19 pandemic.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

References:

1.  Centers for Disease Control and Prevention. Pertussis Cases by Year (1922-2019). Available at: https://www.cdc.gov/pertussis/surv-reporting/cases-by-year.html . Accessed October 2022.

2.  Centers for Disease Control and Prevention. Whooping Cough is Deadly for Babies. Available at:   https://www.cdc.gov/pertussis/pregnant/mom/deadly-disease-for-baby.html . Accessed October 2022.

 

END

 

 

MSCFSFEFUEESELS